Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Engert

Showing results (201-210 of 379) with videos related to

Pageof 38
Sort By:
International Journal of Cancer|May 1, 2018
Whole genome sequencing reveals DICER1 as a candidate predisposing gene in familial Hodgkin lymphomaObul Reddy Bandapalli, Nagarajan Paramasivam, Sara Giangiobbe, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 23, 2004
The ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5Hinrich P Hansen, Andreas Recke, Ulrich Reineke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2005
Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trialsAlexander Shimabukuro-Vornhagen, Heinz Haverkamp, Andreas Engert, et al.
Blood|October 17, 2007
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)Holger Schulz, Ute Rehwald, Franck Morschhauser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2008
Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter studyPeter Reimer, Thomas Rüdiger, Eva Geissinger, et al.
Annals of Hematology|March 11, 2005
Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphomaJan-Peter Glossmann, Jan Oliver Staak, Lucia Nogova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2015
Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Michael Fuchs, et al.
American Journal of Clinical Oncology|June 1, 2004
The HD12 panel of the German Hodgkin Lymphoma Study Group (GHSG): a quality assurance program based on a multidisciplinary panel reviewing all patients' imagingHans Theodor Eich, Susanne Staar, Axel Gossmann, et al.
Blood|February 28, 2013
Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphomaJing Ouyang, Annette Plütschow, Elke Pogge von Strandmann, et al.
Rontgenpraxis; Zeitschrift Fur Radiologische Technik|May 4, 2004
[New therapeutic strategies for Hodgkin lymphoma in cooperation of radiation oncology and medical oncology]Hans Theodor Eich, Rolf-Peter M Müller, Sascha Ansén, et al.
Pageof 38

Showing results (201-210 of 379) with videos related to

Sort By:
Pageof 38
International Journal of Cancer|May 1, 2018
Whole genome sequencing reveals DICER1 as a candidate predisposing gene in familial Hodgkin lymphomaObul Reddy Bandapalli, Nagarajan Paramasivam, Sara Giangiobbe, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 23, 2004
The ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5Hinrich P Hansen, Andreas Recke, Ulrich Reineke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2005
Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trialsAlexander Shimabukuro-Vornhagen, Heinz Haverkamp, Andreas Engert, et al.
Blood|October 17, 2007
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)Holger Schulz, Ute Rehwald, Franck Morschhauser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2008
Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter studyPeter Reimer, Thomas Rüdiger, Eva Geissinger, et al.
Annals of Hematology|March 11, 2005
Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphomaJan-Peter Glossmann, Jan Oliver Staak, Lucia Nogova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2015
Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Michael Fuchs, et al.
American Journal of Clinical Oncology|June 1, 2004
The HD12 panel of the German Hodgkin Lymphoma Study Group (GHSG): a quality assurance program based on a multidisciplinary panel reviewing all patients' imagingHans Theodor Eich, Susanne Staar, Axel Gossmann, et al.
Blood|February 28, 2013
Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphomaJing Ouyang, Annette Plütschow, Elke Pogge von Strandmann, et al.
Rontgenpraxis; Zeitschrift Fur Radiologische Technik|May 4, 2004
[New therapeutic strategies for Hodgkin lymphoma in cooperation of radiation oncology and medical oncology]Hans Theodor Eich, Rolf-Peter M Müller, Sascha Ansén, et al.
Pageof 38